Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 24.06 · gapped above the open, then crossed back over prior close. High/low 24.80 at 6:00 am ET, 23.69 at 12:15 pm ET.
Pacira BioSciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of PCRX revenue | Skew |
|---|---|---|---|
| MCKMcKesson Drug Company | 0.06% | 31.00% | 555× |
| CAHCardinal Health, Inc. | 0.07% | 26.00% | 350× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.”
$225M relationship555× more of PCRX’s book than MCK’s
basisPCRX fy2025 · closed 2025-12 $726MMCK fy2026 · closed 2026-03 $403B
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001628280-26-012297cik 0001396814
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.”
$189M relationship350× more of PCRX’s book than CAH’s
basisPCRX fy2025 · closed 2025-12 $726MCAH fy2026 · closed 2026-06 $254B
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.”
$160M relationship
basisPCRX fy2025 · closed 2025-12 $726M
FILING
“In addition, we will supply EXPAREL product and LG Chem will be responsible for securing regulatory approvals in the licensed territories.”
FILING10-K0001628280-26-012297cik 0001396814
“Since April 2022, all iovera° Smart Tips have been produced by Amphenol.”
FILING10-K0001628280-26-012297cik 0001396814
“In April 2014, we entered into a Strategic Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement (the "EXPAREL Manufacturing and Supply Agreement") with Thermo Fisher Scientific Pharma Services, or Thermo Fisher, to collaborate in the manufacture of EXPAREL.”
FILING10-K0001628280-26-012297cik 0001396814
“In July 2025, we entered into a co-promotion agreement with Johnson & Johnson MedTech, or J&J MedTech, (the "J&J Agreement"), to market and promote the use of ZILRETTA for OA knee pain in the U.S.”
FILING10-K0001628280-26-012297cik 0001396814
“Product development expense increased 44% in 2025 versus 2024, primarily due to a $5.0 million upfront license agreement payment to AmacaThera Inc. for the development and commercialization of PCRX-2002, a long-acting, non-opioid analgesic ropivacaine for postsurgical pain control, as well as $3.2 million related to a key employee holdback.”
FILING10-K0001628280-26-012297cik 0001396814
“In January 2025, we and Jubilant Hollisterstier, LLC, or Jubilant, entered into a Manufacture and Supply Agreement (the "Jubilant Agreement") to collaborate in the manufacture of the diluent for ZILRETTA at Jubilant's Spokane, Washington facility.”
FILING10-K0001628280-26-012297cik 0001396814
“Pursuant to an agreement with the Research Development Foundation, or RDF, we were required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to us under the agreement remain valid.”
FILING10-K0001628280-26-012297cik 0001396814
“We also had in-licensed intellectual property, owned by the Southwest Research Institute, or SwRI, which gave us exclusive rights to SwRI patents covering our proprietary microsphere manufacturing technology used in the production of ZILRETTA.”
FILING10-K0001628280-26-012297cik 0001396814
“Aratana pays us a tiered double-digit royalty on certain net sales made in the U.S., and we are eligible to receive up to $40.0 million upon the achievement of commercial milestones.”
FILING10-K0001628280-26-012297cik 0001396814
Watchlist prices, news filtered to it, and its next report on your desk.
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001628280-26-012297cik 0001396814
Pacira BioSciences, Inc. has 7 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Pacira BioSciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
PCRX (Pacira BioSciences, Inc.) has 7 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TMO +4.46%, in healthcare.